A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia

| November 30, 2010 | 0 Comments

by Wayne Macfadden, MD; Yi-Wen Ma, PhD; J. Thomas Haskins, PhD; Cynthia A. Bossie, PhD; and Larry Alphs, MD, PhD

Dr. Macfadden was with Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey, at the time of this analysis; Dr. Macfadden currently is Medical Director at Princeton Medical Institute, Princeton, New Jersey; Drs. Ma and Haskins are with Johnson & Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey;  and Drs. Bossie and Alphs are with Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey.

Psychiatry (Edgemont) 2010;7(11):23–31

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , ,

Category: Original Research, Past Articles, Psychiatry, Schizophrenia

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.